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OBJECTIVE — To assess whether maternal BMI before pregnancy and weight gain during
pregnancy predicted the risk of islet autoimmunity in genetically susceptible children.
RESEARCH DESIGN AND METHODS — Of 46,939 newborns screened for the high-
risk HLA genotype DR4-DQ8/DR3-DQ2, 1,003 were positive and 885 were followed with serial
blood samples tested for autoantibodies to insulin, GAD, and insulinoma-associated protein 2
(IA2). The end point was deﬁned as repeated positivity for two or three autoantibodies or the
onset of type 1 diabetes (islet autoimmunity).
RESULTS — Thirty-six children developed islet autoimmunity, of whom 10 developed type
1 diabetes. Both maternal BMI 30 kg/m
2 before pregnancy and maternal weight gain 15 kg
predictedtheincreasedriskofisletautoimmunity(hazardratio[HR]2.5,P0.023,andHR2.5,
P  0.015, respectively), independent of maternal diabetes.
CONCLUSIONS — Maternalweightmaypredictriskofisletautoimmunityinoffspringwith
a high genetic susceptibility for type 1 diabetes.
Diabetes Care 32:1904–1906, 2009
T
ype 1 diabetes is caused by speciﬁc
autoimmunity against pancreatic
-cells. The incidence of type 1 dia-
betes is increasing worldwide, and Nor-
way currently has one of the world’s
highestincidencerates(1,2).Theetiology
is multifactorial, determined by a combi-
nation of genetic and nongenetic factors.
In Norway, 2.1% of newborns carry the
HLA genotype DR4-DQ8/DR3-DQ2,
which confers a relative risk for type 1
diabetes in excess of 20 and an estimated
absolute risk of 7% by age 15 years (3,4).
Nongenetic factors have been difﬁcult to
identify. Islet autoimmunity may start as
early as in the 1st year of life before clin-
icaltype1diabeteswithvariableduration
or even in utero (5). Studies have sug-
gested that growth and obesity in child-
hood are associated with risk of type 1
diabetes and islet autoimmunity (6,7),
but we are not aware of previous studies
investigating the role of maternal BMI or
weight gain in pregnancy.
RESEARCH DESIGN AND
METHODS— From July 2001 to De-
cember 2007, the MIDIA (Norwegian ac-
ronym for “Environmental Triggers of
Type 1 Diabetes”) study recruited new-
bornsfromthegeneralpopulationofNor-
way with an HLA genotype DR4-DQ8/
DR3-DQ2 (DRB1*0401-DQA1*03-
DQB1*0302/DRB1*03-DQA1*05-
DQB1*02) conferring high risk of type 1
diabetes. Of the 46,939 newborns geno-
typed, 1,003 (2.14%) carried the high-
risk genotype. From that group, 885
children were followed longitudinally
with questionnaires and gave blood sam-
plesforautoantibodytestingatage3,6,9,
and 12 months and then annually (8).
Children who tested positive for autoan-
tibodies at the age of 12 months or older
were scheduled for retesting more fre-
quently than every 12 months. If positive
for a single autoantibody, the children
were scheduled for retesting every 6th
month; if positive for two or three autoanti-
bodies, they were scheduled for retesting
every3rdmonth.Autoantibodiestoinsulin,
GAD, and insulinoma-associated protein 2
(IA2) were measured using radiobinding
assays at the Hormone Laboratory at Aker
University Hospital (8), which has partici-
pated in the Antibody Standardization Pro-
gram (DASP) since 2003 (9). In 2007, the
disease speciﬁcity was 91% for anti-GAD,
95% for anti-IA2, and 96% for insulin au-
toantibody(IAA),whilethediseasesensitiv-
ity was 50% for anti-GAD, 64% for anti-
IA2, and 22% for IAA. Positivity for two or
moreisletautoantibodiesisastrongpredic-
tor for type 1 diabetes in young children
(10). The end point in this analysis was de-
ﬁned as repeated positivity for two or more
oftheabove-mentionedisletautoantibodies
(on at least two consecutive occasions) or
the onset of type 1 diabetes (islet autoim-
munity). All cases of islet autoimmunity
were negative for autoantibodies at age 3
months,andisletautoantibodiespotentially
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from the end point deﬁnition (8). Mother’s
weight,height,andotherdemographicdata
(Table1)werecollectedusingmailedstruc-
turedquestionnaireswheneachchildwas3
months old, with follow-up information at
age 6, 9, and 12 months. Cox proportional
hazards regression models were used to es-
timate hazard ratios (HRs) and 95% CIs for
islet autoimmunity using Stata (version 10;
College Station, TX). Follow-up time was
counted from birth to the date of the last
bloodsample(noncases)ortothemidpoint
between the date of the last negative blood
sample for islet autoantibodies and the date
of the ﬁrst positive sample for islet autoan-
tibodies (cases with islet autoimmunity).
RESULTS— The descriptive character-
istics are shown in Table 1. Both maternal
BMI 30 kg/m
2 before pregnancy (relative
to 25 kg/m
2) and weight gain of 15 kg
during pregnancy (relative to 15 kg) pre-
dicted an approximate two- to threefold in-
crease in the risk of islet autoimmunity
shown in Table 1. The estimated HRs were
only marginally inﬂuenced by mutual ad-
justment or by adjustment for other poten-
tial confounding factors listed in Table 1.
Forinstance,inaregressionmodelsimulta-
neously including maternal BMI 30
kg/m
2 before pregnancy, maternal weight
gain15kgduringpregnancy,presenceof
ﬁrst-degree relatives with type 1 diabetes,
child’s weight gain at 3–12 months of age,
duration of total breastfeeding, duration of
exclusive breastfeeding, birth order, and
smokinginpregnancy,theHR(95%CI)for
BMI 30 kg/m
2 was 2.27 (1.004–5.15)
and for maternal weight gain 15 kg was
2.60 (1.25–5.41).
CONCLUSIONS— Maternal obesity
before pregnancy and weight gain (15
kg) during pregnancy signiﬁcantly pre-
dicted increased risk of persistent multi-
ple positivity for islet autoantibodies in
offspring with high genetic susceptibility
for type 1 diabetes.
Many factors are associated with
women’sBMIandpregnancyweightgain,
such as diet, physical activity, and socio-
economicstatus(11),butfewsuchfactors
are known to inﬂuence their children’s
risk of developing islet autoimmunity or
type1diabetes(12),makingconfounding
by such factors less likely. Maternal dia-
betesisamongthemostobviouspotential
confounders, but controlling for this in
theregressionanalyseshadlittleinﬂuence
on our main result. Consistent results af-
ter adjustment for the child’s weight gain,
age at weaning, or duration of exclusive
breastfeeding, and also after restricting
the analyses to cases seroconverting be-
fore 12 months of age (data not shown),
Table 1—Association of maternal BMI before pregnancy, weight gain during pregnancy, and other characteristics with risk of persistent
positivity for multiple islet autoantibodies in children in the MIDIA study
Affected Unaffected
Unadjusted HR
(95% CI) P
n 36 797
Follow-up from birth (months) 14.0 (4.5–31)* 28.6 (3.2–86)* NA NA
Sex (female) 21 (58) 411 (48) 1.40 (0.72–2.7) 0.32
Maternal BMI (kg/m
2)
25 21 (58) 540 (66) 1.0 ref.
25–29.9 6 (17) 186 (23) 0.83 (0.33–2.05) 0.68
30 9 (25) 92 (11) 2.48 (1.14–5.4) 0.023
Mean (interquartile range) 26.2 (21.8–29.4) 24.4 (21.3–26.2) 1.07 (1.01–1.13) 0.021
Maternal weight gain (kg)
15 10 (28) 414 (50) 1.0 ref.
15 26 (72) 405 (50) 2.47 (1.19–5.1) 0.015
Mean (interquartile range) 16.1 (13.5–19.0) 14.6 (11.0–18.0) 1.04 (0.99–1.10) 0.14
Child’s weight gain 3–12 months (kg) 3.82 (3.3–4.2) 3.63 (3.1–4.1) 1.33 (0.94–1.89) 0.11
Child’s length gain 3–12 months (cm) 14.75 (14–15) 14.67 (13–16) 1.03 (0.89–1.20) 0.66
Age at weaning (months) 10.25 (8–12) 9.50 (6–12) 1.00 (0.94–1.06) 0.99
Duration exclusive breastfeeding (months) 3.52 (2.25–4.5) 3.29 (1.25–4.5) 1.05 (0.89–1.24) 0.56
First-degree type 1 diabetic relative 11 (31) 52 (6.1) 5.92 (2.91–12.0) 0.001
Maternal pregestational type 1 diabetes 3 (8.3) 19 (2.2) 3.67 (1.12–12.0) 0.031
Maternal gestational diabetes† 0 (0) 12 (1.4) NA NA
Maternal age at birth (years) 31.1 (28.0–33.5) 30.7 (28.0–34.0) 1.01 (0.94–1.09) 0.71
Smoking in pregnancy 3 (8.3) 160 (19) 0.41 (0.12–1.32) 0.14
Maternal education
3 years high school 13 (36) 329 (39) 1.0 ref. Global
4 years university 16 (44) 343 (41) 1.20 (0.58–2.5) 0.89
4 years university 7 (19) 171 (20) 1.00 (0.40–2.5)
Child is ﬁrst born vs. later born 8 (22) 300 (35) 0.54 (0.25–1.18) 0.12
Data are n (%) for categorical variables, mean (interquartile range) for continuous variables, and *mean (range) where indicated. All HRs for continuous variables
are per unit increment (1 kg/m
2 or 1 kg wt gain). Maternal BMI before pregnancy was missing for 31 children, maternal weight gain was missing for 30 children,
gestational diabetes was missing for 47 children, maternal age at birth was missing for 11 children, smoking in pregnancy was missing for 5 children, maternal
education was missing for 6 children, duration of exclusive breast feeding was missing for 16 children, weight of the child at 3 months was missing for 69 children,
length of the child at 3 months was missing for 74 children, weight of the child at 12 months was missing for 144 children, and length of the child at 12 months was
missing for 149 children. †None of the mothers reported type 2 diabetes. The variables used in the regression model for the case group had none missing. NA, not
applicable.
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factors is less likely to explain our obser-
vations.Apotentialweaknessinourstudy
is that maternal height and weight were
self-reported. In the event that self-
reporting leads to some measurement er-
ror, the fact that height and weight were
reported before the mothers had any in-
formation of islet autoantibody positivity
makes it most likely that any bias would
have been nondifferential with respect to
theendpointinourstudyandthusatten-
uated the observed relation with islet au-
toimmunity. Unfortunately, we did not
have any measure of insulin sensitivity of
the mothers, but this could perhaps be
included in future studies.
In conclusion, the current study
adds to the evidence that factors oper-
ating early in life may inﬂuence the risk
of advanced islet autoimmunity, which
in itself strongly predicts type 1 diabe-
tes. As with any novel result, indepen-
dent replication will be needed and
further research is warranted to unravel
the potential mechanisms.
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